Bio-Rad Laboratories (BIO) Projected to Post Quarterly Earnings on Wednesday

Bio-Rad Laboratories (NYSE:BIO) is expected to be issuing its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of $2.25 per share and revenue of $651.3020 million for the quarter. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 5:00 PM ET.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The company had revenue of $651.60 million for the quarter, compared to analyst estimates of $614.82 million. During the same period in the prior year, the firm earned $3.11 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, analysts expect Bio-Rad Laboratories to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $339.92 on Monday. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17. Bio-Rad Laboratories has a twelve month low of $211.43 and a twelve month high of $387.99. The stock’s 50 day moving average is $295.35 and its 200-day moving average is $262.48. The firm has a market capitalization of $9.20 billion, a price-to-earnings ratio of 28.98 and a beta of 0.97.

Wall Street Analysts Forecast Growth

BIO has been the topic of a number of research reports. Royal Bank Of Canada upped their target price on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bio-Rad Laboratories in a research report on Tuesday, October 14th. Wells Fargo & Company upped their target price on Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Finally, Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, August 22nd. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $333.50.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. grew its stake in Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares during the period. WFA of San Diego LLC bought a new position in Bio-Rad Laboratories in the 2nd quarter valued at $222,000. Scopia Capital Management LP bought a new position in Bio-Rad Laboratories in the 2nd quarter valued at $22,862,000. Man Group plc grew its stake in Bio-Rad Laboratories by 1,096.0% in the 2nd quarter. Man Group plc now owns 80,288 shares of the medical research company’s stock valued at $19,375,000 after purchasing an additional 73,575 shares during the period. Finally, LMR Partners LLP bought a new position in Bio-Rad Laboratories in the 2nd quarter valued at $470,000. Institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.